Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HLS TherapeuticsTSX:HLS +2.78%69 3-Year EPS without NRI Growth Rate is 18.90% as of Jun. 2026. GuruFocus rates TSX:HLS with a GF Score™ of 69/100 and a GF Value™ of C$4.38 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 784 Drug Manufacturers companies, HLS Therapeutics ranks better than 65.43% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 18.90% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 2.20% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -9.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of HLS Therapeutics was 93.00% per year. The lowest was -105.90% per year. And the median was -2.60% per year.
HLS Therapeutics (TSX:HLS) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
HLS Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
TSX:HLS vs ZTS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HLS Therapeutics 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where HLS Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
HLS Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 18.90% mean?
HLS Therapeutics (TSX:HLS) has a 3-Year EPS without NRI Growth Rate of 18.90% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for HLS Therapeutics and its competitors. According to the industry distribution chart, HLS Therapeutics ranks #271 out of 784 companies in the Drug Manufacturers industry, placing it in the top 34.6%.
Is HLS Therapeutics' 3-Year EPS without NRI Growth Rate too high?
HLS Therapeutics' current 3-Year EPS without NRI Growth Rate is 18.90%. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.80. HLS Therapeutics' value of 18.90% is 92.9% above this industry median. Based on the distribution chart, HLS Therapeutics ranks #271 out of 784 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, HLS Therapeutics has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' 3-Year EPS without NRI Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, HLS Therapeutics ranks #271 out of 784 companies for 3-Year EPS without NRI Growth Rate. This puts HLS Therapeutics in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.80. HLS Therapeutics' value of 18.90% is 92.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.80, based on 784 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HLS Therapeutics's current 3-Year EPS without NRI Growth Rate of 18.90% is 92.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for HLS Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HLS Therapeutics's current 3-Year EPS without NRI Growth Rate is 18.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Modestly Undervalued. The stock's GF Value™ is C$4.38, compared to a current price of C$3.70 — trading 15.5% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 18.90% and 92.9% above the Drug Manufacturers industry median of 9.80. HLS Therapeutics' overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current 3-Year EPS without NRI Growth Rate is 18.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued.
The current stock price of C$3.70 is trading 15.5% below its estimated GF Value™ of C$4.38.
GuruFocus considers HLS Therapeutics to be Modestly Undervalued.
Key valuation signals for TSX:HLS:
3-Year EPS without NRI Growth Rate: 18.90%
GF Value™: C$4.38 vs. price of C$3.70 (15.5% below fair value)
Industry Position: 92.9% above the Drug Manufacturers median (#271 of 784)
No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
69GF Score
Get the complete analysis for TSX:HLS
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:HLS has been successfully added to your 
